Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
l�ll
Cardiotoxicity of the anticancer therapeutic agent bortezomib Nowis D; Maczewski M; Mackiewicz U; Kujawa M; Ratajska A; Wieckowski MR; Wilczynski GM; Malinowska M; Bil J; Salwa P; Bugajski M; Wojcik C; Sinski M; Abramczyk P; Winiarska M; Dabrowska-Iwanicka A; Duszynski J; Jakobisiak M; Golab JAm J Pathol 2010[Jun]; 176 (6): 2658-68Recent case reports provided alarming signals that treatment with bortezomib might be associated with cardiac events. In all reported cases, patients experiencing cardiac problems were previously or concomitantly treated with other chemotherapeutics including cardiotoxic anthracyclines. Therefore, it is difficult to distinguish which components of the therapeutic regimens contribute to cardiotoxicity. Here, we addressed the influence of bortezomib on cardiac function in rats that were not treated with other drugs. Rats were treated with bortezomib at a dose of 0.2 mg/kg thrice weekly. Echocardiography, histopathology, and electron microscopy were used to evaluate cardiac function and structural changes. Respiration of the rat heart mitochondria was measured polarographically. Cell culture experiments were used to determine the influence of bortezomib on cardiomyocyte survival, contractility, Ca(2+) fluxes, induction of endoplasmic reticulum stress, and autophagy. Our findings indicate that bortezomib treatment leads to left ventricular contractile dysfunction manifested by a significant drop in left ventricle ejection fraction. Dramatic ultrastructural abnormalities of cardiomyocytes, especially within mitochondria, were accompanied by decreased ATP synthesis and decreased cardiomyocyte contractility. Monitoring of cardiac function in bortezomib-treated patients should be implemented to evaluate how frequently cardiotoxicity develops especially in patients with pre-existing cardiac conditions, as well as when using additional cardiotoxic drugs.|Animals[MESH]|Antineoplastic Agents/pharmacology/*toxicity[MESH]|Boronic Acids/pharmacology/*toxicity[MESH]|Bortezomib[MESH]|Cell Line[MESH]|Cell Respiration/drug effects[MESH]|Echocardiography[MESH]|Female[MESH]|Heart Diseases/*chemically induced[MESH]|Heart/drug effects/physiopathology[MESH]|Humans[MESH]|Male[MESH]|Mice[MESH]|Mice, Inbred C57BL[MESH]|Mitochondria, Heart/drug effects/pathology/physiology[MESH]|Myocytes, Cardiac/cytology/drug effects/metabolism/pathology[MESH]|Protease Inhibitors/pharmacology/toxicity[MESH]|Pyrazines/pharmacology/*toxicity[MESH]|Rats[MESH]|Rats, Wistar[MESH]|Ventricular Dysfunction, Left/chemically induced[MESH] |